Abstract 2017P
Background
Small cell lung cancer (SCLC) is one of the most lethal forms of lung cancer, with a 5-year survival rate of approximately 7%. SCLC has been divided into limited stage (LS) and extensive stage (ES). For ES-SCLC the use of immunotherapy (IO) has been introduced in combination with platinum-based chemotherapy (CT), prolonging the overall survival of patients. However, only a small fraction of patients experience a durable clinical benefit from this approach, with no selection criteria able to predict clinical outcome. Here we hypothesize that different mutational profiles could be associated to clinical outcome of patients treated with CT-IO with respect to CT alone.
Methods
A case series of 88 ES-SCLC patients was enrolled. Tumor tissues of patients were analysed with a next-generation sequencing-based assay (Foundation One CDx), analysing 324 genes, selected gene rearrangements, microsatellite instability (MSI) and tumor mutational burden (TMB). Statistical analyses have been performed to study the correlation among clinical characteristics, mutational profiles and clinical outcome has been performed.
Results
For patients with available clinical information, 36 were treated with CT-IO and 50 with CT alone. The 65% of patients were male, and the 35% were female, median age was 71 (range 50-86) years old. The 36.2% of patients were former smokers whereas 53.75% were current smokers, while smoking habits were not available for 16 patients. The most frequently mutated genes were TP53 (98%), RB1 (80%), MLL2 (35%), NOTCH3 (16.2%), MLL (12.5%), RICTOR (8.8%), CDKN2A/B (7.3%), APC (7.3%), MYC (6.3%) and MYCL1 (6.3%). No rearrangements were detected in any patient. With regard to TMB, 25% of patients had low TMB (<6 mut/Mb), 65% of patients had intermediate TMB (6>20 mut/Mb), and 10% of patients had high TMB (>20 mut/Mb). MSI data was available for 67 patients, and all but one patients were stable. Survival analyses and correlation of clinical outcome with mutational profiles are still ongoing.
Conclusions
Our results suggest that a comprehensive genomic profile could help to predict clinical outcome of ES-SCLC patients treated with CT-IO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05